Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung ...

Measuring lung function earlier in life would help identify people at risk of developing chronic obstructive pulmonary disease (COPD) and allow for more timely interventions, according to a new study ...

CHICAGO — Hospital volume affected the length of stay for patients with COPD who elect to have endobronchial valve placement, with some association with costs as well, according to an abstract ...

Staged LVRS offered similar hospital length of stay and complication rates as bilateral LVRS. Both approaches led to clinically significant improvements in pulmonary function. Notably, the staged ...

Pulmonx Corporation (Nasdaq: LUNG) ('Pulmonx” or the 'Company'), a global leader in minimally invasive treatments for lung ...

November is Alpha-1 Awareness Month. It's a genetic condition that can lead to serious lung and liver disease. Right now ...

A leader in interventional pulmonology and advanced bronchoscopy, Dr. Gildea joins Olympus after 22 years with the Cleveland ...

Pulmonx is positioned at the bottom for Revenue Growth, with a negative growth rate. It is also at the bottom for Gross ...

One of the most common genetic diseases, AATD, involves the retention of misfolded alpha 1 antitrypsin (AAT) in hepatocytes, ...

Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.

Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and ...

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsGlendon French - CEO, President & DirectorDerrick ...